| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
13,733 |
12,716 |
$949K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,530 |
3,135 |
$923K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
15,118 |
14,171 |
$653K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,437 |
7,105 |
$353K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
7,485 |
6,071 |
$298K |
| 80053 |
Comprehensive metabolic panel |
22,516 |
18,618 |
$233K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
25,737 |
20,807 |
$213K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,154 |
3,040 |
$197K |
| J9312 |
Injection, rituximab, 10 mg |
16 |
12 |
$143K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
7,247 |
6,519 |
$88K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,119 |
597 |
$82K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,465 |
1,414 |
$57K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,035 |
976 |
$46K |
| 97602 |
|
1,773 |
749 |
$43K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
246 |
226 |
$42K |
| 81001 |
|
8,551 |
7,953 |
$37K |
| 70450 |
Computed tomography, head or brain; without contrast material |
331 |
291 |
$29K |
| 87400 |
|
2,146 |
2,029 |
$27K |
| 71046 |
Radiologic examination, chest; 2 views |
1,969 |
1,844 |
$22K |
| 84484 |
|
1,357 |
1,169 |
$17K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
797 |
322 |
$17K |
| 87088 |
|
1,645 |
1,490 |
$16K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
513 |
232 |
$15K |
| 87430 |
|
770 |
743 |
$15K |
| 87634 |
|
195 |
191 |
$12K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
111 |
78 |
$9K |
| 81025 |
|
2,282 |
2,148 |
$8K |
| 83735 |
|
1,272 |
1,043 |
$8K |
| 71045 |
Radiologic examination, chest; single view |
1,168 |
1,060 |
$8K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,630 |
842 |
$8K |
| 83605 |
|
747 |
640 |
$6K |
| 83690 |
|
762 |
721 |
$6K |
| 87081 |
|
398 |
386 |
$5K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
50 |
48 |
$3K |
| 87420 |
|
170 |
162 |
$3K |
| 85610 |
|
1,028 |
842 |
$3K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
13 |
12 |
$3K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
16 |
12 |
$3K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
34 |
32 |
$3K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
41 |
29 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
223 |
205 |
$2K |
| 86900 |
|
83 |
54 |
$2K |
| 96415 |
|
38 |
25 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,223 |
2,085 |
$2K |
| 82553 |
|
122 |
117 |
$1K |
| 86850 |
|
83 |
54 |
$1K |
| 82550 |
|
143 |
130 |
$816.00 |
| 86901 |
|
84 |
54 |
$724.04 |
| 86300 |
|
39 |
37 |
$629.20 |
| 85730 |
|
270 |
218 |
$602.95 |
| 36415 |
Collection of venous blood by venipuncture |
146 |
94 |
$515.34 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
91 |
74 |
$504.69 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
464 |
338 |
$461.52 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
270 |
251 |
$364.59 |
| 85027 |
|
121 |
63 |
$355.02 |
| 82962 |
|
1,349 |
1,179 |
$329.45 |
| J7050 |
Infusion, normal saline solution, 250 cc |
568 |
210 |
$304.05 |
| 84703 |
|
46 |
43 |
$281.26 |
| 87077 |
|
145 |
110 |
$279.40 |
| 73130 |
|
21 |
12 |
$242.25 |
| 73630 |
|
12 |
12 |
$200.10 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
821 |
679 |
$178.58 |
| 83615 |
|
34 |
30 |
$168.00 |
| 85379 |
|
17 |
15 |
$148.20 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
50 |
43 |
$129.81 |
| 87070 |
|
13 |
12 |
$111.93 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
57 |
52 |
$72.75 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
78 |
74 |
$55.94 |
| 87205 |
|
13 |
12 |
$49.63 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
16 |
12 |
$18.75 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
14 |
13 |
$12.72 |
| 87186 |
|
106 |
74 |
$10.44 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
64 |
62 |
$5.48 |
| J2704 |
Injection, propofol, 10 mg |
178 |
165 |
$2.60 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
98 |
88 |
$0.72 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
40 |
38 |
$0.52 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
192 |
137 |
$0.02 |
| 85018 |
|
19 |
12 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
27 |
25 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
15 |
12 |
$0.00 |
| A6209 |
Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
21 |
12 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
39 |
26 |
$0.00 |
| 85014 |
|
19 |
12 |
$0.00 |